Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CARL
HOLDCarlsmed, Inc. · Healthcare · United States · $294M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Carlsmed, Inc. is a medical technology company specializing in AI-enabled personalized spinal surgery devices. Their flagship product, aprevo, uses predictive analytics to optimize implant designs for individual patient anatomy and surgical outcomes. This innovative approach provides a competitive edge in the complex spinal fusion market by enhancing surgical precision and patient-specific care.
FINANCIAL SUMMARY (USD)
| Year | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13.8M | 27.2M | 50.5M | 91.5% | 63.3M | 76.3M | 107.7M | 46.0% |
| EPS | -4.25 | -6.11 | -2.12 | — | -2.34 | -1.41 | -1.38 | — |
| Shares | 26.5M | 26.5M | 26.7M | +0.6% | 27.3M | — | — | — |
| Debt | 11.4M | 17.2M | 17.4M | 23.7% | 21.9M | — | — | — |
| Equity | -46.1M | -70.6M | 98.9M | — | — | — | — | — |
| Op CF | -17.5M | -25.5M | -29.0M | — | -34.1M | — | — | — |
| Inv CF | -0.1M | -0.2M | -25.5M | — | — | — | — | — |
| Fin CF | 3.2M | 58.5M | 100.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CARL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CARL | Carlsmed, Inc.(you) | $294M | 38 | HOLD |
| EVH | Evolent Health, Inc. | $475M | 37 | HOLD |
| HCAT | Health Catalyst, Inc. | $154M | 44 | HOLD |
| WEAV | Weave Communications, Inc. | $491M | 47 | HOLD |
| PHR | Phreesia, Inc. | $632M | 47 | HOLD |
| LFMD | LifeMD, Inc. | $179M | 22 | SELL |
| CTEV | Claritev Corporation | $368M | 60 | HOLD |
| NURS.V | Hydreight Technologies Inc. | $167M | 57 | HOLD |
| SDGR | Schrödinger, Inc. | $1.1B | 34 | SELL |
| MDRX | Veradigm Inc. | $517M | 59 | HOLD |
Peer medians: ROE -25.6% · P/E 30.1x · Gross margin 55.7%